Oncternal Therapeutics (ONCT) Income Statement (2019 - 2024)
Income Statement report data from Jun 30, 2019 to Sep 30, 2024 for Oncternal Therapeutics (ONCT).
Reported currency: USD
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||||||||||
Total Revenue | 490K (-38.75%) | 800K (+40.35%) | 570K (+90.00%) | 300K (+66.67%) | 180K (+63.64%) | 110K (-45.00%) | 200K (+17.65%) | 170K (-55.26%) | 380K (+100.00%) | 190K (-74.67%) | 750K (+33.93%) | 560K (-73.71%) | 2.13M (+142.05%) | 880K (+17.33%) | 750K (-52.83%) | 1.59M (+169.49%) | 590K (-4.84%) | 620K (+6.90%) | 580K (-21.62%) | 740K (+37.04%) | 540K (-19.40%) | 670K |
Gross Profit | 490K (-38.75%) | 800K (+40.35%) | 570K (+90.00%) | 300K (+66.67%) | 180K (+63.64%) | 110K (-45.00%) | 200K (+17.65%) | 170K (-55.26%) | 380K (+100.00%) | 190K (-74.67%) | 750K (+33.93%) | 560K (-73.71%) | 2.13M (+142.05%) | 880K (+17.33%) | 750K (-52.83%) | 1.59M (+169.49%) | 590K (-4.84%) | 620K (+6.90%) | 580K (-21.62%) | 740K (+37.04%) | 540K (-19.40%) | 670K |
Operating Expenses | ||||||||||||||||||||||
Research And Development | 6.45M (-2.42%) | 6.61M (+9.08%) | 6.06M (-9.15%) | 6.67M (-10.83%) | 7.48M (+13.68%) | 6.58M (-27.13%) | 9.03M (+2.61%) | 8.80M (+4.27%) | 8.44M (-3.65%) | 8.76M (+25.50%) | 6.98M (+15.95%) | 6.02M (-32.81%) | 8.96M (+72.64%) | 5.19M (+32.74%) | 3.91M (+30.77%) | 2.99M (-1.97%) | 3.05M (-20.16%) | 3.82M (+41.48%) | 2.70M (+5.06%) | 2.57M (-17.36%) | 3.11M (-84.96%) | 21M |
Selling General And Administrative | 2.73M (-10.49%) | 3.05M (-7.29%) | 3.29M (+0.92%) | 3.26M (+5.50%) | 3.09M (+0.65%) | 3.07M (-7.53%) | 3.32M (+0.91%) | 3.29M (+0.61%) | 3.27M (+1.24%) | 3.23M (-12.23%) | 3.68M (+40.46%) | 2.62M (-6.43%) | 2.80M (-17.16%) | 3.38M (+21.15%) | 2.79M (+91.10%) | 1.46M (-24.35%) | 1.93M (-17.52%) | 2.34M (-11.03%) | 2.63M (+11.91%) | 2.35M (-1.26%) | 2.38M (+46.91%) | 1.62M |
Operating Expenses | 9.18M (-4.97%) | 9.66M (+3.32%) | 9.35M (-5.84%) | 9.93M (-6.05%) | 11M (+9.53%) | 9.65M (-21.86%) | 12M (+2.15%) | 12M (+3.25%) | 12M (-2.34%) | 12M (+12.48%) | 11M (+23.38%) | 8.64M (-26.59%) | 12M (+37.34%) | 8.57M (+27.72%) | 6.71M (+50.79%) | 4.45M (-10.64%) | 4.98M (-19.16%) | 6.16M (+15.57%) | 5.33M (+8.33%) | 4.92M (-10.38%) | 5.49M (-75.37%) | 22M |
Operating Income | ||||||||||||||||||||||
Operating Income | -8.68M (-2.03%) | -8.86M (+0.91%) | -8.78M (-8.92%) | -9.64M (-7.22%) | -10.39M (+8.91%) | -9.54M (-21.42%) | -12.14M (+1.93%) | -11.91M (+5.21%) | -11.32M (-3.99%) | -11.79M (+18.97%) | -9.91M (+22.65%) | -8.08M (-16.18%) | -9.64M (+25.36%) | -7.69M (+29.03%) | -5.96M (+108.39%) | -2.86M (-34.85%) | -4.39M (-20.61%) | -5.53M (+16.42%) | -4.75M (+13.64%) | -4.18M (-15.56%) | -4.95M (-77.10%) | -21.62M |
EBITDA | -8.68M (-2.03%) | -8.86M (+0.91%) | -8.78M (-8.92%) | -9.64M (-7.22%) | -10.39M (+8.91%) | -9.54M (-21.42%) | -12.14M (+1.93%) | -11.91M (+5.21%) | -11.32M (-3.99%) | -11.79M (+18.97%) | -9.91M (+22.65%) | -8.08M (-16.18%) | -9.64M (+25.36%) | -7.69M (+29.03%) | -5.96M (+108.39%) | -2.86M (-34.85%) | -4.39M (-20.61%) | -5.53M (+16.42%) | -4.75M (+13.64%) | -4.18M (-15.56%) | -4.95M (-77.10%) | -21.62M |
Other Income / Expenses | ||||||||||||||||||||||
Interest Income | 220K (-26.67%) | 300K (-23.08%) | 390K (-17.02%) | 470K (-11.32%) | 530K (-8.62%) | 580K (-12.12%) | 660K (+26.92%) | 520K (+160.00%) | 200K (+300.00%) | 50K (+400.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | - | - | 10K (-66.67%) | 30K (-50.00%) | 60K (0.00%) | 60K |
Net Interest Income | 220K (-26.67%) | 300K (-23.08%) | 390K (-17.02%) | 470K (-11.32%) | 530K (-8.62%) | 580K (-12.12%) | 660K (+26.92%) | 520K (+160.00%) | 200K (+300.00%) | 50K (+400.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | - | - | 10K (-66.67%) | 30K (-50.00%) | 60K (0.00%) | 60K |
Other Non Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.28M |
Net Income | ||||||||||||||||||||||
Income Before Tax | -8.46M (-1.17%) | -8.56M (+2.03%) | -8.39M (-8.41%) | -9.16M (-7.10%) | -9.86M (+9.92%) | -8.97M (-21.93%) | -11.49M (+0.79%) | -11.40M (+2.52%) | -11.12M (-5.28%) | -11.74M (+18.59%) | -9.90M (+22.68%) | -8.07M (-16.20%) | -9.63M (+25.39%) | -7.68M (+29.08%) | -5.95M (+132.42%) | -2.56M (-41.69%) | -4.39M (-20.61%) | -5.53M (+16.67%) | -4.74M (+13.94%) | -4.16M (-14.93%) | -4.89M (-78.60%) | -22.85M |
Net Income From Continuing Operations | -8.46M (-1.17%) | -8.56M (+2.03%) | -8.39M (-8.41%) | -9.16M (-7.10%) | -9.86M (+9.92%) | -8.97M (-21.93%) | -11.49M (+0.79%) | -11.40M (+2.52%) | -11.12M (-5.28%) | -11.74M (+18.59%) | -9.90M (+22.68%) | -8.07M (-16.20%) | -9.63M (+25.39%) | -7.68M (+29.08%) | -5.95M (+132.42%) | -2.56M (-41.69%) | -4.39M (-20.61%) | -5.53M (+16.67%) | -4.74M (+13.94%) | -4.16M (-14.93%) | -4.89M (-78.60%) | -22.85M |
Net Income | -8.46M (-1.17%) | -8.56M (+2.03%) | -8.39M (-8.41%) | -9.16M (-7.10%) | -9.86M (+9.92%) | -8.97M (-21.93%) | -11.49M (+0.79%) | -11.40M (+2.52%) | -11.12M (-5.28%) | -11.74M (+18.59%) | -9.90M (+22.68%) | -8.07M (-16.20%) | -9.63M (+25.39%) | -7.68M (+29.08%) | -5.95M (+132.42%) | -2.56M (-41.69%) | -4.39M (-20.61%) | -5.53M (+16.67%) | -4.74M (+13.94%) | -4.16M (-14.93%) | -4.89M (-78.60%) | -22.85M |